Br J Surg:直肠癌放化疗后及系膜切除术后的排便功能和生活质量研究

2016-10-19 MedSci MedSci原创

相比传统手术,直肠局部切除术有望提供一个更好的功能结果。本研究的目的是,比较放化疗后行局部切除或传统手术的直肠癌患者的生活质量和肠功能。这是一个回顾性多中心研究。局部切除术与直肠系膜切除术比较。使用验证问卷(欧洲癌症研究与治疗组织(EORTC)QLQ-C30, EORTC QLQ-CR29和纪念斯隆-凯特琳癌症中心肠功能仪器)调查生活质量和功能。平均随访49个月(范围13-95)。对只行局部切除术

相比传统手术,直肠局部切除术有望提供一个更好的功能结果。本研究的目的是,比较放化疗后行局部切除或传统手术的直肠癌患者的生活质量和肠功能。

这是一个回顾性多中心研究。局部切除术与直肠系膜切除术比较。使用验证问卷(欧洲癌症研究与治疗组织(EORTC)QLQ-C30, EORTC QLQ-CR29和纪念斯隆-凯特琳癌症中心肠功能仪器)调查生活质量和功能。平均随访49个月(范围13-95)。对只行局部切除术的患者和需要再次根治性手术的患者数据进行了进一步的分析。P < 0.010时具有统计学意义。

平均便秘评分在局部切除组明显直肠系膜切除术组更好(3.8 (95% CI 0.3 to 7.2) versus 19.8 (12.1 to 27.4); P < 0.001)。与行直肠系膜切除术患者相比,局部切除术患者的不完全排空感觉更少(平均得分 3.7 (3.4 to 4.0) versus 2.8 (2.5 to 3.1); P < 0.001),15分钟内第二次排便情况更好(平均得分 3.6 (3.3 to 3.9) versus 3.0 (2.7 to 3.3); P = 0.006)。只行局部切除术的患者的得分比直肠系膜切除术患者的得分更好,尤其是肠道功能。直肠系膜切除术患者的得分比局部切除术后还需要根治性手术的患者更好。

行局部切除术的患者较接受全直肠系膜切除术的患者,有更好的生活质量和肠功能。

原始出处:

Pucciarelli S1, Giandomenico F2, De Paoli A3, Gavaruzzi T4, Lotto L4,5, Mantello G6, Barba C7, Zotti P8, Flora S3,8, Del Bianco P9.Bowel function and quality of life after local excision or total mesorectal excision following chemoradiotherapy for rectal cancer.Br J Surg. 2016 Oct 5. doi: 10.1002/bjs.10318. [Epub ahead of print]

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1634596, encodeId=f172163459649, content=<a href='/topic/show?id=8d3d5661e2b' target=_blank style='color:#2F92EE;'>#排便#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56617, encryptionId=8d3d5661e2b, topicName=排便)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a25722217738, createdName=kkunny, createdTime=Sun Mar 05 05:46:00 CST 2017, time=2017-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876839, encodeId=082218e683909, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Tue Apr 04 23:46:00 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172055, encodeId=f86b1e20552e, content=非常感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20971999626, createdName=laymankey, createdTime=Mon Jan 23 00:41:06 CST 2017, time=2017-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287885, encodeId=82cd128e885c2, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57318, encryptionId=4d185e31825, topicName=放化疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Fri Oct 21 12:46:00 CST 2016, time=2016-10-21, status=1, ipAttribution=)]
    2017-03-05 kkunny
  2. [GetPortalCommentsPageByObjectIdResponse(id=1634596, encodeId=f172163459649, content=<a href='/topic/show?id=8d3d5661e2b' target=_blank style='color:#2F92EE;'>#排便#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56617, encryptionId=8d3d5661e2b, topicName=排便)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a25722217738, createdName=kkunny, createdTime=Sun Mar 05 05:46:00 CST 2017, time=2017-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876839, encodeId=082218e683909, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Tue Apr 04 23:46:00 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172055, encodeId=f86b1e20552e, content=非常感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20971999626, createdName=laymankey, createdTime=Mon Jan 23 00:41:06 CST 2017, time=2017-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287885, encodeId=82cd128e885c2, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57318, encryptionId=4d185e31825, topicName=放化疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Fri Oct 21 12:46:00 CST 2016, time=2016-10-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1634596, encodeId=f172163459649, content=<a href='/topic/show?id=8d3d5661e2b' target=_blank style='color:#2F92EE;'>#排便#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56617, encryptionId=8d3d5661e2b, topicName=排便)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a25722217738, createdName=kkunny, createdTime=Sun Mar 05 05:46:00 CST 2017, time=2017-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876839, encodeId=082218e683909, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Tue Apr 04 23:46:00 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172055, encodeId=f86b1e20552e, content=非常感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20971999626, createdName=laymankey, createdTime=Mon Jan 23 00:41:06 CST 2017, time=2017-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287885, encodeId=82cd128e885c2, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57318, encryptionId=4d185e31825, topicName=放化疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Fri Oct 21 12:46:00 CST 2016, time=2016-10-21, status=1, ipAttribution=)]
    2017-01-23 laymankey

    非常感谢分享!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1634596, encodeId=f172163459649, content=<a href='/topic/show?id=8d3d5661e2b' target=_blank style='color:#2F92EE;'>#排便#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56617, encryptionId=8d3d5661e2b, topicName=排便)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a25722217738, createdName=kkunny, createdTime=Sun Mar 05 05:46:00 CST 2017, time=2017-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876839, encodeId=082218e683909, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Tue Apr 04 23:46:00 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172055, encodeId=f86b1e20552e, content=非常感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20971999626, createdName=laymankey, createdTime=Mon Jan 23 00:41:06 CST 2017, time=2017-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287885, encodeId=82cd128e885c2, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57318, encryptionId=4d185e31825, topicName=放化疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Fri Oct 21 12:46:00 CST 2016, time=2016-10-21, status=1, ipAttribution=)]
    2016-10-21 yzh399

相关资讯

CA:只有55%的II、III期直肠癌患者进行了指南推荐的治疗

指南推荐II、III期直肠癌患者进行三联疗法(手术、放疗和化疗)。最近的一项研究表明,虽然在过去的十年中,使用新辅助化疗和放疗治疗直肠癌在增加,但是只有约一半的患者接受指南推荐的标准诊疗。 来自美国癌症协会和俄勒冈健康与科学大学(OHSU)的研究人员对68182例II、III期直肠癌患者进行了研究。比较了2004-2006年 vs 2007-2009年 vs 2010-2012年患者的治疗情

2016国际共识指南——直肠癌的临床靶区勾画发布

临床靶区和近危及器官勾画是现代放射治疗的基本步骤,放射肿瘤学家定义了7步勾画步骤,为临床医师在直肠癌放疗过程中临床靶区的勾画提供了指导。全文获取:下载地址:指南下载 (需要扣积分2分, 梅斯医学APP免积分下载)

世界全新术式让她避免“人工肛门”之苦!

34岁的未婚外籍华人吴小姐罹患低位直肠癌,为保证根治肿瘤,传统手术往往不得不切除肛门后粪便改道,即在其腹壁上做永久性的人工肛门;为减少病人痛苦,提高病人生活质量, 复旦大学附属上海市第五人民医院普外科柯重伟教授团队克服困难,为其实施了代表目前国际直肠癌手术最新进展、最高水平的高难度的“经肛门联合经腹腔镜低位直肠癌根治术” (TaTME),既保住了病人的肛门,腹部也未留下疤痕。9月20日术后第13天

Ann Surg:经肛门直肠全系膜切除术,效果如何?

本研究的目的是,报告国际经肛门直肠全系膜切除术(taTME)注册表中,良性和恶性直肠病变的短期临床和肿瘤结果。TaTME是最新的经肛门的微创技术,避免了复杂的盆腔解剖。已有相关小队列的结局研究发表,但是更大系列可以进一步评估taTME对更广泛手术的人群的安全性和有效性。对来自23个国家的66个注册单位的数据进行了分析。主要终点是“质量好的TME手术” ,次要终点是短期的不良事件。使用单因素和多因素

JAMA Intern Med:结肠镜筛查**二氧化碳气腹

“虽然许多美国人经常接受结肠镜筛查,但没有随机试验量化筛选对结直肠癌的发病率和死亡率的影响,”挪威奥斯陆大学经济系健康管理的Michael Bretthauer博士说,“当前发表在JAMA Internal Medicine的NordICC试验,是目前已知的对结肠镜筛查的首次评价,比较了筛查或不筛查对结直肠癌发病率和死亡率的影响。”虽然结直肠癌是高收入国家的第二大癌症,但大多数欧洲国家并没有引入结

J Clin Oncol:直肠癌新辅助放化疗后接受手术的更佳时间? 7周or11周? (GRECCAR-6)

直肠癌新辅助放化疗后(RCT) 的病理完全缓解(pCR; ypT0N0)与良好的预后相关。几项回顾性试验研究了在RCT后延期手术的效果。这项研究的目的是为了评估增加最后一次RCT到手术的时间对pCR率的影响。 GRECCAR6试验是一个多中心,随机,开放,平行对照III期试验。患有中或下段cT3/T4或Tx N+结肠癌患者接受 RCT (45到50 Gy,氟尿嘧啶或卡培他滨)入组研究。患